A Phase I/II Trial to Evaluate the Safety and Tolerability of Ides (IgG Endopeptidase) to Eliminate Donor Specific HLA Antibodies (DSAs) and Prevent Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients.
Phase of Trial: Phase I/II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs IdeS (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 03 Aug 2017 Combined results of trials ( NCT02224820, NCT02426684, NCT02475551) assessing the efficacy of IdeS with regard to desensitization and transplantation of a kidney from an HLA-incompatible donor.published in the New England Journal of Medicine
- 02 Aug 2017 According to a Hansa Medical media release, combined results from this and 2 other trials (CT 244081and 230633) have been published in the New England Journal of Medicine.
- 20 Jul 2017 According to a Hansa Medical media release, the company expects to enrol and treat all patients by the end of 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History